We have assembled a leading team of advisors with deep expertise in our target disease indications.
Inflammatory Bowel Disease
Dr. Hanauer is an internationally recognized expert on the treatment of inflammatory bowel disease. He currently serves as the medical director of the Digestive Disease Center at Northwestern University Feinberg School of Medicine and as the Clifford Joseph Barborka Professor of Medicine. After earning his medical degree from the University of Illinois, Dr. Hanauer completed his internship and residency in internal medicine followed by a fellowship in gastroenterology at the University of Chicago. There Dr. Hanauer was mentored by one of the great clinicians in American gastroenterology, the legendary Dr. Joseph B. Kirsner. Dr. Hanauer held a Professorship in Medicine at Chicago named for Dr. Kirsner.
As Chairman of the Gastrointestinal Drugs Advisory Committee at the US Food and Drug Administration, Dr. Hanauer authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease”. From 2014-2015, he served as president of the American College of Gastroenterology (ACG), where he has been a member of the ACG Board of Trustees since 2006, an officer of the ACG since 2010 and a contributing committee member since 1989. He has represented the ACG at the FDA related to development of end-points for IBD in a series of “GREAT” meetings. He edited Nature Reviews Gastroenterology & Hepatology and chaired the ACG Finance Committee from 2011 to 2012. Dr. Hanauer has also held leadership positions in the American Gastroenterological Association (AGA) as chair of the Sections on Infection, Immunology and Inflammatory Bowel Disease as well as Clinical Practice, and served on the AGA Governing Board as a Counselor for Clinical Research. Internationally, he is a member of the European Crohn’s and Colitis Organization (ECCO) and is a former chairman of the International Organization for IBD (IOIBD).
Dr. Hanauer was awarded the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the AGA Janssen Award for Clinical Excellence in GI in 2004. He is currently an Associate Editor for Clinical Gastroenterology and Hepatology. In addition, Dr. Hanauer has worked with the American Board of Internal Medicine serving on the Gastroenterology sub-specialty. He has also held leadership positions within the Crohn’s & Colitis Foundation of American and in 2011 received CCFA’s Scientific Achievement Award for Clinical Research. Over the course of his career, Hanauer has authored or co-authored hundreds of peer-reviewed journal articles, books, book chapters, monographs, and editorials.
Dr. Hyams is one of the world’s leading experts in pediatric inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. As Head of the Division of Digestive Diseases, Hepatology, and Nutrition at Connecticut Children’s Medical Center, he has led pivotal clinical trials for therapeutic agents in IBD and directed a long-term natural history registry that has described the course of almost 2000 children newly diagnosed with IBD. Dr. Hyams is the recent recipient of a $10.4M grant from the National Institutes of Health investigating the response of children newly diagnosed with ulcerative colitis to standardized therapies. He has worked with the FDA developing endpoints for pediatric clinical trials, has published more than 250 peer reviewed articles, and is the co-editor of one of the standard pediatric digestive disease textbooks, Pediatric Gastrointestinal and Liver Disease. Dr. Hyams was the first pediatrician to ever receive the prestigious Scientific Achievement in IBD Clinical Research Award from the Crohn’s & Colitis Foundation of America. He graduated from University of Pennsylvania School of Medicine and conducted his residency and fellowship at Boston Children’s Hospital.
Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School. Dr. Korzenik has been involved in IBD research and care of patients for almost 25 years, with his research focusing on 1) translational research in IBD and 2) investigating environmental influences in IBD, with a focus on their common nexus of the intestinal microbiome. Dr. Korzenik is the author of almost 60 peer-reviewed articles and research papers. He speaks frequently at professional meetings and is an active member of many professional committees. Dr. Korzenik has been the principal investigator of over a dozen research projects, ranging from studies of diet and probiotics to international comparisons of IBD. Dr. Korzenik earned his bachelor’s degree from Harvard College in 1980 and his medical degree from Albert Einstein College of Medicine in the Bronx, New York, in 1987. He was a resident at Harvard-affiliated Beth Israel Deaconess Hospital in Boston from 1987 to 1990 and fellow in gastroenterology and clinical epidemiology at Yale University School of Medicine Hospital from 1991 to 1994. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.
Dr. Rieder is an investigator at the Department of Pathobiology and an Associate Staff at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with inflammatory bowel diseases (IBD) with a special emphasis on the field of pathogenesis, prediction and therapy of IBD.
Dr. Rieder has published more than 60 articles and book chapters and has been recognized for his expertise and he serves on multiple committees, speakers’ panels, steering committees and editorial boards. He is a member of the European Crohn’s and Colitis Organization (ECCO), the German Gastroenterology Association, the American Gastroenterology Association, the America Physiological Society, the American College of Physicians, and the Crohn’s and Colitis Foundation. He is the associate editor of Clinical and Translational Gastroenterology, section editor of Annals of Gastroenterology, on the editorial boards of the Journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, BMC Gastroenterology, American Journal of Physiology: Gastrointestinal and Liver Physiology and Gastroenterology and Hepatology Journal. Dr. Rieder is the senior author of the new ECCO guidelines for Ulcerative colitis, the first author of the ECCO consensus on Fibrostenosing IBD and co-author of the new ECCO guidelines in Crohn’s disease.
He received his medical degree from the Ludwig-Maximilians-University Medical School in Germany. He underwent training in Internal Medicine / Gastroenterology at the Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, Germany and a residency in Internal Medicine and fellowship in Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic in Cleveland, Ohio. Dr. Rieder has performed research fellowships at Harvard Medical School and the Cleveland Clinic.
William Sandborn, MD, is a board-certified gastroenterologist who is one of the world’s top experts in the management of ulcerative colitis and Crohns disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health.
In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health.
A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators.
With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for inflammatory bowel disease. Dr. Sandborn is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques.
His clinical trials have been instrumental to developing modern treatments for IBD.
Dr. Sandborn has published nearly 600 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology.
Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn.
Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn’s disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn’s disease.
Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn’s Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn’s and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for “Excellence in Action” in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field’s leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Dr. Diehl is a leading researcher in the field of nonalcoholic fatty liver disease (NAFLD) with a long standing interest in liver injury and repair. She is currently the Director of the Duke Liver Center and the Florence McAlister Professor of Medicine at the Duke University School of Medicine.
Dr. Diehl has conducted seminal research in many areas, including liver regeneration, the role of cytokines in liver disease, and hepatocellular cancer. In addition, she has conducted the definitive work in understanding the important role of Hedgehog signaling proteins in liver pathobiology, from liver regeneration, to hepatic fibrosis, to activation of stellate cells, growth of progenitor cells, and development of cirrhosis. Dr. Diehl was also one of the first researchers to demonstrate that fatty liver is not a reversible innocuous condition, but a frequent cause of severe liver damage, evolving into non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
Dr. Diehl has been an active participant in the NIDDK-funded Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), a national consortium comprised of 8 university medical centers selected to generate a national registry for patients with NAFLD and to conduct multicenter treatment trials for this disorder. Diehl has received extensive grant funding from the National Institutes of Health and has authored more than 250 peer-reviewed articles. She is a recipient of numerous awards, including the Leon Schiff Award, the Hans Popper Award, the Sheila Sherlock Award from the British Society of Gastroenterology, and the American Association for the Study of Liver Diseases Distinguished Achievement Award.
She received her M.D. from Georgetown University, followed by residency and a fellowship in gastroenterology at Johns Hopkins University.
Joel E. Lavine, MD, PhD, is tenured Professor of Pediatrics, also in the Institute of Human Nutrition, Division of Gastroenterology, Hepatology and Nutrition at Columbia College of Physicians and Surgeons. A noted physician-scientist, his research centers around the etiopathogenesis, genetics, natural history, environmental provocation, biomarker/bioimaging development and treatment of particular pediatric liver diseases, with emphasis on fatty liver.
Since 2002, Prof. Lavine has been the sole Pediatric Principal Investigator funded by the NIDDK for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). He is the sole pediatric co-author for the Guidelines for NASH from the American Association for the Study of Liver Diseases (AASLD), as well as the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG). Prof. Lavine has served as the primary author on numerous clinical trials in adult and pediatric NAFLD/NASH, and along with Dr. Vos (primary author), served as corresponding author for the manuscript published in 2020 in Gastroenterology on “Factors to Consider in the Development of Drugs for Pediatric NAFLD”, along with representatives from the FDA, EMA, and numerous industry partners.
He chaired and co-chaired numerous NIH committees, including the NASH CRN Steering Committee, the NASH CRN Database Committee, and the NASH CRN Pediatric Committee. He has Chaired numerous NIH Grant Review Panels, the NIDDK Data and Safety Monitoring Board of the Cholestatic Liver Disease Research and Education Network (ChiLDReN), and TEEN-LABS (Longitudinal Assessment for Bariatric Surgery.
Prof. Lavine earned his doctorate in Molecular Biology in 1980 at the University of California, Santa Barbara, and his Medical Degree from the University of California, San Diego, in 1984. He is board certified in pediatrics and pediatric gastroenterology, where he trained at the University of California, San Francisco. He has been a Division Chief at UC San Diego and Columbia University for 25 years.
Dr. Mary Rinella is a Professor of Medicine at Northwestern University’s Feinberg School of Medicine. For more than 15 years, she has worked on both basic mechanisms of non-alcoholic steatohepatitis (NASH) and clinical aspects of NASH. Her current interests are in clinical trial development, the association between NASH metabolic comorbidities, and the recurrence of NASH after liver transplantation. Her work has earned her recognition as a global authority in these fields.
Dr. Rinella currently serves as Chair of the NASH American Association for the Study of Liver Diseases (AASLD) Task Force and is past Chair of the NAFLD/NASH Special Interest Group at the AASLD. She is the Director of the Northwestern Fatty Liver Program.
She received her medical degree from the University of Illinois, Chicago, fulfilled her residency at the University of Chicago Hospitals, and completed her fellowship at Northwestern University McGaw Medical Center.
Dr. Albert is a member of the Department of Medicine Division of Pulmonary Sciences and Critical Care Medicine at University of Colorado School of Medicine and is the department’s Vice Chair for Clinical Affairs. Albert’s decades-long research program has focused on laboratory and clinical studies targeting the pathophysiology and treatment of ARDS, and clinical trials aimed at trying to reduce and treat acute exacerbations of COPD.
In ARDS, Dr. Albert has led research on the use of intermittent sighs incorporated into mechanical ventilation based on the idea that stretching the lung causes the type 2 pneumocytes to secrete surfactant. In addition, Dr. Albert conducted a number of laboratory-based investigations that first defined the mechanisms by which prone positioning improved oxygenation in ARDS. The results of these studies led Dr. Albert to propose a new mechanism explaining the pathophysiology of ARDS and the potential role of prone positioning in decreasing mortality of ARDS by decreasing ventilator-induced lung injury. He has been the principal investigator in multiple multicenter, randomized controlled trials in ARDS and COPD.
Albert graduated from the University of Colorado School of Medicine in 1971, and completed the first two years of residency training there before transferring to the University of Washington to complete his residency. After a fellowship in CU’s top-ranked pulmonary program, Albert returned to the University of Washington, where he remained until becoming Chief of Medicine at Denver Health in 1997.
Dr. Bruce Levy is Chief of the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital (BWH) and on faculty at Harvard Medical School as the Parker B. Francis Professor of Medicine. He is board-certified in critical care medicine and pulmonary disease and has broad interest in ARDS, asthma, bronchiectasis and chronic obstructive pulmonary disease. He received his medical degree from the University of Pennsylvania School of Medicine (now the Perelman School of Medicine). He then completed a residency in internal medicine, a chief medical residency, and a fellowship in pulmonary and critical care medicine at BWH. His post-doctoral research training was performed in the laboratory of Professor Charles Serhan, who remains a collaborator.
The Levy laboratory’s research on Resolvin E1 in ARDS and asthma models laid the foundation for Thetis’ TP-317 program. Dr. Levy’s laboratory continues to determine new mechanisms and pathways to resolve pulmonary inflammation, infection or injury through the roles of naturally-derived, specialized pro-resolving mediators, and to translate these findings to the pathobiology of important airway diseases. His work has helped lead to more than 175 peer-reviewed publications, over 10 patents awarded or pending, and continuous funding from the National Institutes of Health since 1993. He is an elected member of the ASCI, AAP and Interurban Clinical Club. He is active in the American Thoracic Society and currently serves as Chair of the Publication Policy Committee and member of the Board of Directors.
Charles Nicholas Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and also Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine; He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan’s pioneering studies on the chemistry-medicine interface have resulted in the discovery of the Specialized Pro-resolving Mediators (SPMs), a super-family of biochemical mediators that actively orchestrate the resolution of inflammation and provide the molecular underpinnings for a new era in inflammation resolution pharmacology.
Charles received a BS in biochemistry from Stony Brook University followed by a Doctorate in experimental pathology and medical sciences from New York University School of Medicine. He was a visiting scientist and post-doctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson (Nobel Laurate Medicine 82). In 1987, he joined the faculty at Harvard Medical School and received an honorary degree from Harvard University (1996).
He has received several awards including an NIH MERIT award and has delivered > 50 keynote and plenary lectures. Among these recent awards are: the 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology Bonazinga Award, The American College of Rheumatology Hench (Nobel Laurate) Award Lecture in 2011 presented by the Mayo Clinic Hench Society, and Mérieux 2013 Laureate.
In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. Recently, he received the International Eicosanoid Research Foundation’s 2017 Lifetime Achievement Award and the American Society of Investigative Pathology 2018 Rous Whipple Award and the 2018 Gaddum International Prize and Award Lecture from the British Pharmacology Society.